The Company is a clinical stage research and development pharmaceutical company.
The Company has developed a unique resveratrol platform product primarily targeting treatment of neuro-inflammation. The product candidate, called JOTROL, has many potential indications of use for rare diseases, which of the Company primarily are targeting Mucopolysaccharidoses Type 1, Friedreich's Ataxia, and MELAS. In the larger disease areas, The Company are primarily targeting Parkinson's Disease and Mild Cognitive Impairment/early Alzheimer's disease.
HISTORY
2016 The Company incorporated in Delaware in January 2016.
2021 On August 30, 2021, the Company filed a Certificate of Amendment to the Certificate of Incorporation with the State of Delaware to change its name to Jupiter Neurosciences, Inc.
2024 Its common stock is listed on The Nasdaq Capital Market and its stock symbol is “JUNS.”
Headquarters
1001 North Us Hwy 1, Suite 504
Jupiter; Florida;
Postal Code: 33477
Contact Details: Purchase the Jupiter Neurosciences Inc. report to view the information.
Website: http://www.jupiterneurosciences.com
EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.
Request a demo of the EMIS serviceTo view more information, Request a demonstration of the EMIS service